Interleukin-1β (IL-1β)
Interleukin-1 beta (IL-1β), encoded by the IL1B gene, is a pro-inflammatory cytokine of the interleukin-1 family and one of the principal drivers of fever and systemic inflammation.
Interleukin-1 beta (IL-1β), encoded by the IL1B gene, is a pro-inflammatory cytokine of the interleukin-1 family and one of the principal drivers of fever and systemic inflammation. It is produced chiefly by activated macrophages, monocytes, and dendritic cells, and its release requires two separate signals. The first, typically a toll-like receptor engaging nuclear factor kappa B (NF-κB), transcribes an inactive 31 kDa precursor; the second assembles an inflammasome such as the NLRP3 inflammasome, which activates caspase-1 (CASP1) to cleave that precursor into the 17 kDa mature form. Because IL-1β carries no signal peptide it cannot leave by the classical secretory pathway, and can exit through Gasdermin D (GSDMD) pores in the plasma membrane among other unconventional pathways. This two-key arrangement is what keeps a cytokine this destructive from being released on transcription alone.
Mature IL-1β signals through IL-1R1 in complex with the accessory protein IL-1RAcP, recruiting MyD88 and the IRAK kinases to activate NF-κB and MAPK cascades. The transcriptional response includes further inflammatory mediators such as interleukin-6 and tumor necrosis factor alpha, and the enzymes that generate prostaglandins, notably cyclooxygenase-2 — IL-1β induces the machinery rather than the lipid mediators themselves. The system is restrained at several points: the receptor antagonist IL-1Ra occupies IL-1R1 without signaling, and the decoy receptor IL-1R2 binds the cytokine without transducing.
Sustained IL-1β production underlies chronic inflammatory and fibrotic disease, including rheumatoid arthritis, sepsis-associated organ injury, neurodegeneration, metabolic disease, and diabetic complications, and it works within a network alongside TNF, Interleukin-6 (IL-6), and Interleukin 18 (IL-18). Blockade is clinically established rather than prospective: recombinant IL-1Ra, an IL-1β-neutralizing antibody, and a soluble receptor trap are used in the hereditary autoinflammatory syndromes, where the response is near-complete, and in gout and adult-onset Still disease. Trial evidence that IL-1β blockade lowers recurrent cardiovascular events independently of lipid lowering established inflammation itself as a treatable cardiovascular target. Measurement of the cytokine — in serum, urine, or tissue homogenates — may serve as a pharmacodynamic or diagnostic biomarker in selected contexts, though its short half-life and low circulating concentrations limit routine use.
- Expression of nuclear factor kappa B-associated long non-coding RNAs in drug-naïve and valproic acid-treated epilepsy patients. PMID 43034957
Where the papers sit
20 papers from the last 6 months study Interleukin-1β (IL-1β) directly
Study type 1 clinical trial · 4 observational · 6 human data · 8 preclinical · 1 unclassified
Themes no clear themes · 1 new direction
Those 20 do not share a common subject.
-
Inflammatory disease research here ranges from tissue repair and autoinflammatory disorders to cancer, neurodegeneration, osteoarthritis, gout, infection, and metabolic disease. IL-1β appears mainly as a shared inflammatory marker or pathway component rather than a unifying biological question. The approaches include immunotherapy, small molecules, nanoplatforms, biomarker assays, and clinical studies, with outcomes spanning pain, organ injury, immunity, and cognition. This heterogeneous set shows no common research direction.
IL-1β becomes a self-reinforcing metabolic-epigenetic driver of immunotherapy resistance
The subject is ALDH9A1-driven resistance to anti-PD-1 therapy in non-small cell lung cancer; rather than serving only as an inflammatory mediator or therapeutic target, IL-1β activates NF-κB and ALDH9A1 in a feedback loop that increases tumor-cell chromatin accessibility, promotes myeloid-derived suppressor-cell polarization, and drives CD8+ T-cell exhaustion. Blocking IL-1β disrupted this loop, suppressed tumor progression, and restored anti-PD-1 sensitivity, assigning IL-1β a role as an upstream controller of a tumor-metabolic immune-evasion circuit 42574617Aug.
Papers
The 20 papers from the last 6 months that study Interleukin-1β (IL-1β) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (20)
- PMID 42154340
- Active immunotherapy against IL-1β restores tissue repair under chronic inflammation. Proceedings of the National Academy of Sciences of the United States of America · 2 Nov 2026 PMID 42970687
- IL-1β/IL-6 inflammatory crosstalk drives DNA methylation and histone remodeling associated with cytokine induced senescence in luminal breast cancer. Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 18 Oct 2026 PMID 42892641
- Bellidifolin alleviates doxorubicin-induced hepatotoxicity: a study integrating network pharmacology, molecular docking, and experimental validation. Die Naturwissenschaften · 22 Sept 2026 PMID 42771163
- A Dual-Membrane Biomimetic Nanoplatform Enables Triple-Modal Therapy Against SARS-CoV-2 Through Viral Decoy, Inflammation Neutralizing, and Intracellular RNAi. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 7 Sept 2026 PMID 42702867
- Biologic-biologic and biologic-JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases. Seminars in arthritis and rheumatism · 3 Sept 2026 PMID 42691741
- Serum VIP and IL-1β Levels Are Associated With Anxiety and Depression in Patients With Parkinson's Disease: A Cross-Sectional Study. Brain and behavior · 1 Sept 2026 PMID 42677804
- Anti-neuroinflammatory and neuroprotective effects of sweroside and swertiamarin from Swertia bimaculata in an in vitro microglial activation model. Biochemical and biophysical research communications · 31 Aug 2026 PMID 42673911
- Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes. Cell metabolism · 25 Aug 2026 PMID 42641605
- Inhibition of cyclin-dependent kinase 8 modulates chondrocyte transition to hypertrophy and provides in vivo protection against spontaneous osteoarthritis. Bone research · 24 Aug 2026 PMID 42637709
- Multiplex Sensing and Molecular Classification of Osteoarthritis via a Biomarker-Responsive Dual-Nanozyme Activity Sensor Array. Analytical chemistry · 18 Aug 2026 PMID 42610914
- Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy. Proceedings of the National Academy of Sciences of the United States of America · 10 Aug 2026 PMID 42574617
- SSGJ-613 Alleviates Pain and Reduces the Risk of Acute Flares in Patients With Gout: A Randomized, Double-Blind, Phase II Study. International journal of rheumatic diseases · 30 Jul 2026 PMID 42530081
- Radiobiological effects of flattening filter and flattening filter free radiotherapy x-ray on inflammatory and apoptotic pathways in cardiac and pulmonary tissues in an MCF-7 xenograft breast cancer model. Journal of radiation research · 7 Jul 2026 PMID 42411639
- Key targets and mechanisms by which gut microbiota-derived metabolites regulate Alzheimer's disease through the immune - inflammatory pathway: Based on network pharmacology and molecular docking. PloS one · 6 Jul 2026 PMID 42406869
- Allograft inflammatory factor-1 in macrophages promotes renal tubular cell epithelial-mesenchymal transition via the NF-κB/IL-1β axis in diabetic kidney disease. Biochemical and biophysical research communications · 25 Jun 2026 PMID 42349122
- Protocol for assessment of pain biomarkers in orthopaedic patients undergoing total knee arthroplasty in a tertiary care hospital and neuroimmunopharmacology laboratory in South Australia: a cross-sectional matched-subject observational study. BMJ open · 22 Jun 2026 PMID 42331593
- Integrative single-cell profiling and explainable AI identify monocyte-metabolic signatures as diagnostic biomarkers and candidate therapeutic targets in tuberculosis. Archives of microbiology · 22 Jun 2026 PMID 42329418
- Co-Delivery of Chemo and Immune Drugs by Prussian Blue Nanocubes for Combinational Therapy and T1-T2W MR Imaging of MDA-MB-231. ACS applied bio materials · 16 Jun 2026 PMID 42299821
- Blood Protein Test Predicts Lung Cancer Years before Diagnosis. Cancer discovery · 16 Jun 2026 PMID 42299102
By study type
Clinical trials (1)
- SSGJ-613 Alleviates Pain and Reduces the Risk of Acute Flares in Patients With Gout: A Randomized, Double-Blind, Phase II Study. International journal of rheumatic diseases · 30 Jul 2026 PMID 42530081
Observational studies and case reports (4)
- Expression of nuclear factor kappa B-associated long non-coding RNAs in drug-naïve and valproic acid-treated epilepsy patients. Molecular biology reports · 15 Nov 2026 PMID 43034957
- Biologic-biologic and biologic-JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases. Seminars in arthritis and rheumatism · 3 Sept 2026 PMID 42691741
- Serum VIP and IL-1β Levels Are Associated With Anxiety and Depression in Patients With Parkinson's Disease: A Cross-Sectional Study. Brain and behavior · 1 Sept 2026 PMID 42677804
- Protocol for assessment of pain biomarkers in orthopaedic patients undergoing total knee arthroplasty in a tertiary care hospital and neuroimmunopharmacology laboratory in South Australia: a cross-sectional matched-subject observational study. BMJ open · 22 Jun 2026 PMID 42331593
Human data, design not indexed (6)
- IL-1β/IL-6 inflammatory crosstalk drives DNA methylation and histone remodeling associated with cytokine induced senescence in luminal breast cancer. Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 18 Oct 2026 PMID 42892641
- Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes. Cell metabolism · 25 Aug 2026 PMID 42641605
- Multiplex Sensing and Molecular Classification of Osteoarthritis via a Biomarker-Responsive Dual-Nanozyme Activity Sensor Array. Analytical chemistry · 18 Aug 2026 PMID 42610914
- Key targets and mechanisms by which gut microbiota-derived metabolites regulate Alzheimer's disease through the immune - inflammatory pathway: Based on network pharmacology and molecular docking. PloS one · 6 Jul 2026 PMID 42406869
- Integrative single-cell profiling and explainable AI identify monocyte-metabolic signatures as diagnostic biomarkers and candidate therapeutic targets in tuberculosis. Archives of microbiology · 22 Jun 2026 PMID 42329418
- Blood Protein Test Predicts Lung Cancer Years before Diagnosis. Cancer discovery · 16 Jun 2026 PMID 42299102
Preclinical: animal, cell and lab studies (8)
- Active immunotherapy against IL-1β restores tissue repair under chronic inflammation. Proceedings of the National Academy of Sciences of the United States of America · 2 Nov 2026 PMID 42970687
- Bellidifolin alleviates doxorubicin-induced hepatotoxicity: a study integrating network pharmacology, molecular docking, and experimental validation. Die Naturwissenschaften · 22 Sept 2026 PMID 42771163
- Anti-neuroinflammatory and neuroprotective effects of sweroside and swertiamarin from Swertia bimaculata in an in vitro microglial activation model. Biochemical and biophysical research communications · 31 Aug 2026 PMID 42673911
- Inhibition of cyclin-dependent kinase 8 modulates chondrocyte transition to hypertrophy and provides in vivo protection against spontaneous osteoarthritis. Bone research · 24 Aug 2026 PMID 42637709
- Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy. Proceedings of the National Academy of Sciences of the United States of America · 10 Aug 2026 PMID 42574617
- Radiobiological effects of flattening filter and flattening filter free radiotherapy x-ray on inflammatory and apoptotic pathways in cardiac and pulmonary tissues in an MCF-7 xenograft breast cancer model. Journal of radiation research · 7 Jul 2026 PMID 42411639
- Allograft inflammatory factor-1 in macrophages promotes renal tubular cell epithelial-mesenchymal transition via the NF-κB/IL-1β axis in diabetic kidney disease. Biochemical and biophysical research communications · 25 Jun 2026 PMID 42349122
- Co-Delivery of Chemo and Immune Drugs by Prussian Blue Nanocubes for Combinational Therapy and T1-T2W MR Imaging of MDA-MB-231. ACS applied bio materials · 16 Jun 2026 PMID 42299821
Unclassified: not yet indexed with MeSH (1)
- A Dual-Membrane Biomimetic Nanoplatform Enables Triple-Modal Therapy Against SARS-CoV-2 Through Viral Decoy, Inflammation Neutralizing, and Intracellular RNAi. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 7 Sept 2026 PMID 42702867
Written from 20 PubMed abstracts, each one listed by PMID above. Published: 2026-06-14. Last written: 2026-09-24 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.